Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma

Takahiko Horiguchi; Soichi Tachikawa; Junichi Kasahara; Masashi Doi; Mamoru Shiga

doi:10.1055/s-0031-1300355

Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma

Takahiko Horiguchi, Soichi Tachikawa, Junichi Kasahara, Masashi Doi, Mamoru Shiga

Respiratory Medicine & Clinical Allergy

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Pranlukast hydrate (CAS 103177-37-3, ONO-1078) was administered to 20 patients with bronchial asthma, and examined the effects of this agent on serum eosinophil cationic protein (ECP) levels and peripheral blood eosinophil counts. The mean serum ECP level in the group comprised of patients with bronchial asthma was significantly higher than that in the control group comprised of healthy adults. In responders in whom improvement in asthmatic symptoms was observed, serum ECP levels were significantly decreased compared to the pretreatment values 4 weeks after commencement of pranlukast hydrate administration. However, there were no changes in non- responders. There was no correlation between serum ECP level and peripheral blood eosinophil count before administration of pranlukast hydrate. However, there was a correlation 4 weeks after administration was started. Iris suggested that pranlukast hydrate inhibits eosinophilic activity in patients with bronchial asthma.

Original language	English
Pages (from-to)	35-37
Number of pages	3
Journal	Arzneimittel-Forschung/Drug Research
Volume	49
Issue number	1
DOIs	https://doi.org/10.1055/s-0031-1300355
Publication status	Published - 1999

All Science Journal Classification (ASJC) codes

Drug Discovery

Access to Document

10.1055/s-0031-1300355

Fingerprint Dive into the research topics of 'Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma'. Together they form a unique fingerprint.

Cite this

@article{7eee2db9c3034fd89996e48039aa64ee,

title = "Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma",

abstract = "Pranlukast hydrate (CAS 103177-37-3, ONO-1078) was administered to 20 patients with bronchial asthma, and examined the effects of this agent on serum eosinophil cationic protein (ECP) levels and peripheral blood eosinophil counts. The mean serum ECP level in the group comprised of patients with bronchial asthma was significantly higher than that in the control group comprised of healthy adults. In responders in whom improvement in asthmatic symptoms was observed, serum ECP levels were significantly decreased compared to the pretreatment values 4 weeks after commencement of pranlukast hydrate administration. However, there were no changes in non- responders. There was no correlation between serum ECP level and peripheral blood eosinophil count before administration of pranlukast hydrate. However, there was a correlation 4 weeks after administration was started. Iris suggested that pranlukast hydrate inhibits eosinophilic activity in patients with bronchial asthma.",

author = "Takahiko Horiguchi and Soichi Tachikawa and Junichi Kasahara and Masashi Doi and Mamoru Shiga",

year = "1999",

doi = "10.1055/s-0031-1300355",

language = "English",

volume = "49",

pages = "35--37",

journal = "Drug Research",

issn = "2194-9379",

publisher = "Thieme",

number = "1",

}

TY - JOUR

T1 - Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma

AU - Horiguchi, Takahiko

AU - Tachikawa, Soichi

AU - Kasahara, Junichi

AU - Doi, Masashi

AU - Shiga, Mamoru

PY - 1999

Y1 - 1999

N2 - Pranlukast hydrate (CAS 103177-37-3, ONO-1078) was administered to 20 patients with bronchial asthma, and examined the effects of this agent on serum eosinophil cationic protein (ECP) levels and peripheral blood eosinophil counts. The mean serum ECP level in the group comprised of patients with bronchial asthma was significantly higher than that in the control group comprised of healthy adults. In responders in whom improvement in asthmatic symptoms was observed, serum ECP levels were significantly decreased compared to the pretreatment values 4 weeks after commencement of pranlukast hydrate administration. However, there were no changes in non- responders. There was no correlation between serum ECP level and peripheral blood eosinophil count before administration of pranlukast hydrate. However, there was a correlation 4 weeks after administration was started. Iris suggested that pranlukast hydrate inhibits eosinophilic activity in patients with bronchial asthma.

AB - Pranlukast hydrate (CAS 103177-37-3, ONO-1078) was administered to 20 patients with bronchial asthma, and examined the effects of this agent on serum eosinophil cationic protein (ECP) levels and peripheral blood eosinophil counts. The mean serum ECP level in the group comprised of patients with bronchial asthma was significantly higher than that in the control group comprised of healthy adults. In responders in whom improvement in asthmatic symptoms was observed, serum ECP levels were significantly decreased compared to the pretreatment values 4 weeks after commencement of pranlukast hydrate administration. However, there were no changes in non- responders. There was no correlation between serum ECP level and peripheral blood eosinophil count before administration of pranlukast hydrate. However, there was a correlation 4 weeks after administration was started. Iris suggested that pranlukast hydrate inhibits eosinophilic activity in patients with bronchial asthma.

UR - http://www.scopus.com/inward/record.url?scp=0032894980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032894980&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1300355

DO - 10.1055/s-0031-1300355

M3 - Article

C2 - 10028377

AN - SCOPUS:0032894980

VL - 49

SP - 35

EP - 37

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 1

ER -

Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this